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Major depressive disorder is among the most
commonly diagnosed disabling mental diseases.
Several non-pharmacological treatments of depres-
sion upregulate adenosine concentration and/or
adenosine A1 receptors (A1R) in the brain. To test
whether enhanced A1R signaling mediates antide-
pressant effects, we generated a transgenic mouse
with enhanced doxycycline-regulated A1R expres-
sion, specifically in forebrain neurons. Upregulating
A1R led to pronounced acute and chronic resil-
ience toward depressive-like behavior in various
tests. Conversely, A1R knockout mice displayed an
increased depressive-like behavior and were resis-
tant to the antidepressant effects of sleep depri-
vation (SD). Various antidepressant treatments in-
crease homer1a expression in medial prefrontal
cortex (mPFC). Specific siRNA knockdown of hom-
er1a in mPFC enhanced depressive-like behavior
and prevented the antidepressant effects of A1R up-
regulation, SD, imipramine, and ketamine treatment.
In contrast, viral overexpression of homer1a in the
mPFC had antidepressant effects. Thus, increased
expression of homer1a is a final common pathway
mediating the antidepressant effects of different
antidepressant treatments.
INTRODUCTION
Major depression is a common disease associated with high
individual suffering, increased risk of suicide, and an enormous
economic burden for the society (Greenberg et al., 2003a,2003b). Despite numerous pathophysiological hypotheses
such as inadequate response to stressors resulting in alterations
in neuroplasticity, neurogenesis, and neuro-immunological regu-
lation, knowledge about the neurobiology of depression and the
mechanism of action of therapeutic measures such as antide-
pressants, sleep deprivation (SD), and electroconvulsive therapy
(ECT) are still rudimentary (Benedetti and Colombo, 2011; Kato,
2009; Krishnan and Nestler, 2010).
While the anticonvulsant, neuroprotective, and sleep-promot-
ing effects of adenosine are widely appreciated (Fredholm et al.,
2005), little is known about its potential role in mood disorders
(Burnstock et al., 2011; Sadek et al., 2011; van Calker and
Biber, 2005). Adenosine’s actions are mediated by four receptor
subtypes, A1, A2A, A2B, and A3 (Fredholm et al., 2001). It is
known that SD evokes an increased release of adenosine in
the brain and upregulation of adenosine A1 receptors (A1Rs) in
rodents and humans (Basheer et al., 2007; Elmenhorst et al.,
2009; Elmenhorst et al., 2007). Two other non-pharmacological
interventions for depression ECT and deep brain stimulation
(DBS) are associated with an increased release of adenosine
and stimulation of A1R (Bekar et al., 2008; Hamani et al.,
2010; Sadek et al., 2011; van Calker and Biber, 2005). Further-
more, recent direct experimental data indicate that adenosine
agonists have antidepressant activity (Hines et al., 2013).
Thus, increased A1R signaling might elicit antidepressant
effects.
To test directly this hypothesis, we have generated a trans-
genic mouse model with conditionally enhanced A1R expres-
sion in forebrain neurons under the control of the CaMKII
promoter. We report that increasing A1R expression, by
switching on the transgene in these mice, evokes both resil-
ience against depressive-like behavior and antidepressant
effects in a chronic depression model. We further show that
the antidepressant effects of A1R upregulation as well as those
of SD, imipramine, and ketamine are all mediated by an induc-
tion of homer1a expression in the medial prefrontal cortexNeuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc. 549
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Figure 1. Generation of a MouseModel with Tetracycline-Regulated
Enhanced Expression of Adenosine A1 Receptor Specifically in
Forebrain Neurons
(A) The tetracycline-regulated (Tet-Off) expression of the mouse A1 receptor
(A1R). Ca
2+/calmodulin-dependent kinase II (CaMKII) promoter controls the
expression of the tetracycline transactivator (tTA) gene product, which induces
the simultaneous transcription of the A1R and mCherry specifically in forebrain
neurons, by binding to a tetracycline responsive element (TRE) containing a
bidirectional promoter (PminiCMV). Thus, the gene expression could be blocked
by tetracycline or its stable analog doxycycline (Dox).
(B) Spatial distribution of mCherry expression in the mouse brain (green,
neuronal nuclei marker NeuN; red, anti-mCherry/RFP staining).
(C) Relative mRNA expression of A1R in cerebellum (cer), cortex (ctx), hippo-
campus (hip), and striatum (str) of wild-type (WT), A1 OFF, A1mice Dox treated
from birth; A1 ON, A1 mice Dox treated from birth, followed by 4 weeks Dox
withdrawal, normalized to s12, GAPDH, and actin (n = 4).
(D) Representative western blot demonstrating the effect of 4 weeks Dox
treatment on mCherry and A1R protein expression in different brain regions of
WT and A1 mice (n = 4).
(E) Densitometric quantification of A1R protein expression in different brain
regions of WT and TG mice normalized to actin (n = 4).
One-way ANOVA with Bonferroni post hoc test: *p < 0.05, **p < 0.01, n.s., not
significant. Data are expressed as the means ± SEM.
See also Figures S3A and S3B.
550 Neuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc.(mPFC), a neuronal immediate-early gene that has been impli-
cated in the etiology of major depression (Rietschel et al.,
2010).
RESULTS
Generation of Transgenic Mice with Inducible A1R
Expression Specifically in Forebrain Neurons
To investigate directly the behavioral effects of enhanced
neuronal A1R expression, we generated a binary transgenic
mousemodel with an inducible gene expression system contain-
ing a tetracycline responsive bidirectional promoter controlling
the simultaneous expression of mouse A1R and mCherry
reporter gene with the Tet-OFF system (Figure 1A). The design
and cloning of the tetracycline-regulated expression system
was previously described and in vitro functionally characterized
(Serchov et al., 2012). The generation of the A1R transgenic
mouse line was performed by pronuclear injections of the
above-described construct into C57/Bl6 oocytes. To achieve
region- and cell-specific upregulation of A1R, we used CaMKII-
tTA mice, which express the transactivator under the control of
CaMKII promoter specifically in forebrain neurons (Mayford
et al., 1996) (Figure 1A).
Evaluation of theDoxycycline-Regulated A1R Transgene
Expression
In order to prevent potential effects of enhanced transgenic A1R
expression during development, all mice were maintained on
doxycycline until weaning. Thereafter, mice were either further
kept on doxycycline or without doxycycline for 4 weeks to allow
transgene expression. The characterization of the spatial distri-
bution of the transgene expression, using immunohistochemical
staining against the reporter gene, revealed that the mCherry
expression has a labeling pattern typical for CaMKII promoter
activity, primary distributed to forebrain neurons, similar to
the previous reports (Mayford et al., 1996; Odeh et al., 2011)
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Figure 2. Antidepressant Effects of Enhanced A1R Signaling
(A) Spontaneous activity in open field test: total distance of movement of WT
and A1 mice (n = 12).
(B) Immobility time in tail suspension test (TST) (n = 8).
(C) Immobility time in day 2 of forced swim test (FST) of WT and A1mice (n = 8).
(D) Immobility time in day 2 of FST of WT mice 1 hr and 24 hr after single i.p.
injection of saline or 3 mg/kg A1R agonist MRS5474 (n = 6).
One-way ANOVAwith Bonferroni post hoc test: **p < 0.01, n.s., not significant.
Data are expressed as the means ± SEM.
See also Figure S1.(Figure 1B). The evaluation of the doxycycline-regulated
transgene expression demonstrated that doxycycline treatment
completely suppressed themCherry immunofluorescence label-
ing (Figure S3A) andmRNA and protein expression in the brain to
undetectable levels (Figures 1D and S3B). The analysis of A1R
mRNA and protein expression levels showed about 2-fold upre-
gulation in cortex and hippocampus in mice without doxycycline
(A1 ON) in comparison to doxycycline-treated animals (A1 OFF)
or their wild-type (WT) littermates (Figures 1C–1E). LowmCherry
expression and no significant enhancement of A1R mRNA and
protein levels were detected in striatum and cerebellum, exam-
ined as control regions (Figures 1C–1E and S3B).
Anxiolytic and Antidepressant Effects of the Enhanced
A1R Signaling
To investigate potential effects of enhanced A1R expression on
the behavior, we subjected the mice to a battery of behavioraltests. The spontaneous activity and exploratory drive, evaluated
by the total traveled distance in the open field test were not
significantly affected in A1 ON mice (Figure 2A). However,
switching on the transgene (A1 ON) induced robust anxiolytic ef-
fects in three well-characterized behavioral tests for anxiety:
open field test (Figure S1A), elevated plus maze (Figures S1B
and S1C), and dark-light box (Figures S1D and S1E). The novel
object recognition test, T-maze, and Morris water maze showed
that the upregulated A1R had no significant effect on learning
and memory (Figures S1F–S1K). The two basic tests for depres-
sive-like behavior—tail suspension test (TST) and classical
forced swim test (FST)—revealedmarked antidepressant effects
of enhanced A1R expression, evident by significant decrease of
the immobility time (Figures 2B and 2C). To test further the anti-
depressant effect of A1R signaling, we intraperitoneally injected
(i.p.) WT mice with the selective A1R agonist MRS5474 (Tosh
et al., 2012). MRS5474 induced a rapid antidepressant effect in
FST, performed 1 hr after the injection (Figure 2D).
Antidepressant Effect of Enhanced A1R Expression in
the Chronically Despaired Mice
To investigate further the antidepressant effect of enhanced A1R
expression, we adopted the recently published chronic behav-
ioral despair model (Kumar et al., 2010; Stone and Lin, 2011;
Sun et al., 2011) (Figure 3A; see Experimental Procedures for
details). In this paradigm (see Figure 3A for experimental design),
WT and A1 OFF mice did not show any differences either during
acquisition (induction phase) or in maintenance of depressive-
like behavior (test phase) (Figures 3B and S2C). However, turning
on transgenic A1R expression after the induction phase (A1
OFF + 4 weeks ON), significantly reduced the immobility time
(Figure 3B) and significantly increased travel distance (Fig-
ure S2C) to control levels, though doxycycline treatment of WT
mice did not significantly affect the induction and maintenance
of the depressive-like behavioral state in the chronic behavioral
despair mouse model (Figures S2A and S2B). A1 ON mice ex-
hibited pronounced resilience toward induction of the behavioral
despair with significantly reduced immobility time and increased
traveled distance during the induction phase but developed
finally the same depressive-like behavior as A1 OFF mice at
day 5 (Figures 3C and S2D). The maintenance of enhanced
A1R expression (A1 ON) or turning on transgenic A1R expression
after the induction phase (A1 OFF + 4 weeks ON) significantly
reduced chronic depressive-like behavior in the test phase (Fig-
ures 3C and S2D). On the other hand, turning off transgenic A1R
expression after the induction phase (A1 ON + 4 weeks OFF)
prevented this amelioration and the mice displayed depres-
sive-like behavior indistinguishable from A1 OFF animals (Fig-
ures 3C and S2D). Similar results were obtained with TST that
was performed before induction phase (TST1) and at the test
phase (TST2) (see Figure 3A for experimental design). No differ-
ence in immobility time betweenWT and A1OFFmice was found
in both TST tests, whereas A1 ON mice displayed a significantly
decreased immobility time at both time points (Figure 3D).
Furthermore, after the induction phase both WT and A1 ON
mice displayed decreased sucrose preference (SPT2) as
compared to sucrose preferences obtained before the induction
phase (SPT1) (Figure 3E). While WT mice chronically maintainedNeuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc. 551
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Figure 3. Antidepressant Effect of Enhanced A1R Expression in the
Chronically Despaired Mice
(A) Schematic illustration of the experimental protocol: control sucrose pref-
erence test (SPT1) and TST1 were performed at day 2 to day 0 before the
552 Neuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc.the decreased sucrose consumption (SPT3), enhanced trans-
genic A1R expression (A1 ON) for 4 weeks significantly amelio-
rated this anhedonic state (Figure 3E). The i.p. injection of A1R
agonist MRS5474 had a significant antidepressant effect also
in chronically despaired mice, when applied 1 hr before the
test phase (Figure 3F).
Behavioral Effects of A1R Deletion
To explore further the effects of A1R signaling, we investigated
the depressive-like behavior of A1RKO mice in the chronic
behavioral despair mouse model (see Figure 4A for experimental
design). A1RKO mice displayed more rapid and more pro-
nounced development of behavioral despair during the induction
phase than WT mice, which was further maintained for 4 weeks,
represented by significantly increased immobility time and
decreased traveled distance at the induction and test phase (Fig-
ures 4B and S2E). WT mice responded to imipramine treatment
(20 mg/kg/day for 4 weeks) and to 6 hr of sleep deprivation (SD)
with a decrease in immobility time and increased travel distance
(Figures 4B and S2E), concordant with the antidepressant
effects of both treatments. Recovery sleep abolished the effects
of SD on depressive-like behavior in WT animals, very similar to
humans, where the antidepressant effects of SD are also lost
after sleep (Figures 4B and S2E). Despaired A1RKO mice re-
sponded to imipramine treatment, but not to SD (Figures 4B
and S2E). Similar results were obtained with TST (see Figure 4Ainduction of the behavioral despair. Then the mice were despaired by 10 min
swim sessions for 5 consecutive days: day 1 to day 5 (induction phase), fol-
lowed by second SPT2 (day 6 to day 8). For the following 4 weeks, the mice
were kept undisturbed in their home cages and divided into five groups: WT,
wild-type mice; A1 OFF, mice with doxycycline-suppressed A1R expression
for the whole experiment; A1 OFF + 4weeks ON, mice with doxycycline-sup-
pressed A1R expression till day 5 followed by 4 weeks of activation of the A1R
expression by doxycycline withdrawal; A1 ON, mice with activated A1R
expression for the whole experiment; A1 ON + 4weeks OFF, mice with
activated A1R expression till day 5 followed by 4 weeks suppression of the
A1R expression by doxycycline treatment. On day 32 the TST2 and the last
10min swim session (test phase) were performed, followed by SPT3 (day 32 to
day 35).
(B) Immobility time during the induction phase (day 1 to day 5) of WT (n = 20)
and A1 OFF (n = 20) mice and during the test phase (day 32) of WT (n = 20), A1
OFF (n = 10) and A1 OFF + 4 weeks ON mice (n = 10).
(C) Immobility time during the induction phase (day 1 to day 5) of A1 OFF
(n = 20) and A1 ON (n = 20) mice and during the test phase (day 32) of A1 OFF
(n = 10), A1 OFF + 4 weeks ON (n = 10), A1 ON (n = 10), and A1 ON + 4 weeks
OFF mice (n = 10). (B and C) Two-way ANOVA with Bonferroni post hoc test:
*p < 0.05, **p < 0.01, ***p < 0.001; #p < 0.05, ##p < 0.01, ###p < 0.001 in
comparison to day 1, and xxp < 0.01 in comparison to day 5.
(D) Immobility time in TST of control (TST1) and chronically despaired (TST2)
WT (n = 10), A1 OFF (n = 10), and A1 ON (n = 10) mice. Two-way ANOVA with
Bonferroni post hoc test: *p < 0.05, **p < 0.01; ##p < 0.01, and ###p < 0.001 in
comparison to TST1.
(E) Sucrose preference of control (SPT1), despaired (SPT2), and chronically
despaired (SPT3) WT (n = 10) and A1 ON mice (n = 10). Two-way ANOVA with
Bonferroni post hoc test: *p < 0.05 and #p < 0.01 in comparison to SPT1.
(F) Immobility time during the induction phase of WT mice (n = 10) and during
the test phase 1 hr after i.p. injection of saline or 3 mg/kg MRS5474. Two-way
ANOVA with Bonferroni post hoc test: *p < 0.05; ##p < 0.01, ###p < 0.001 in
comparison to day 1, and xp < 0.01 in comparison to day 5.
Data are expressed as the means ± SEM.
See also Figure S2.
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Figure 4. Behavioral Effects of A1R Deletion
(A) Schematic illustration of the experimental pro-
tocol: control SPT1 and TST1 were performed
at day 2 to day 0 before the induction of the
behavioral despair. Then, the mice were despaired
by 10 min swim sessions for 5 consecutive days:
day 1 to day 5 (induction phase). For the following
4 weeks, the WT and A1RKO mice were kept un-
disturbed in their home cages and divided into four
groups: CDM, chronically despaired mice; Imi,
despaired mice treated for 4 weeks with Imipra-
mine in the drinking water. SD, CDM mice sleep
deprived for 6 hr on day 32. RS, CDM mice sleep
deprived for 6 hr on day 32, followed by 18 hr of
recovery sleep. CDM and Imi mice were subjected
to TST2 and the last 10 min swim session (test
phase) on day 32, followed by SPT3 (day 32 to
day 35). The TST2 and test phase of SD and
RS mice were performed on day 32 and day 33,
respectively.
(B) Immobility time during the induction phase
(n = 40) and test phase (n = 10) of WT and A1RKO
mice. Two-way ANOVA with Bonferroni post hoc
test: *p < 0.05, **p < 0.01, ***p < 0.001; #p < 0.05,
##p < 0.01, ###p < 0.001 in comparison to day 1
and xp < 0.05, xxp < 0.01 in comparison to day 5.
(C) Immobility time in TST of control (TST1) and
CDM, Imi, SD, and RS (TST2) WT and A1RKOmice
(n = 10). Two-way ANOVA with Bonferroni post
hoc test: *p < 0.05, ##p < 0.01 in comparison to
TST1 and xxp < 0.01, xxxp < 0.001 in comparison
to CDM.
(D) Sucrose preference of control (SPT1), CDM,
and Imi (SPT2) WT and A1RKO mice (n = 10).
Two-way ANOVA with Bonferroni post hoc test:
*p < 0.05, **p < 0.01 and #p < 0.01 in comparison
to SPT1.
Data are expressed as the means ± SEM.
See also Figure S2E.for experimental design). Also in TST1, A1RKO showed signifi-
cantly increased immobility time compared to WT mice (Fig-
ure 4C). At TST2, WT animals showed reduced immobility time
after imipramine treatment and SD, whereas A1RKO mice did
not respond to SD with reduced immobility time in TST2,
albeit the effect of imipramine was present (Figure 4C). In the
sucrose preference test, A1RKO mice displayed significantly
pronounced anhedonic behavior (SPT1) as compared to WT
mice. Whereas sucrose intake was reduced in WT mice after
chronic despair induction (SPT2), no further decrease was
seen in A1RKO animals. Imipramine treatment increased su-
crose intake in both A1RKO and WT animals (SPT2) to WT con-
trol levels (Figure 4D). Taken together, these results demonstrate
a prominent depressive-like behavior of A1RKO mice and show
that A1RKO mice are responsive to imipramine treatment, but
not to SD.Neuron 87, 549–56Homer1a Expression Level in the
mPFC Correlates with Depressive-
like Behavior
Considering the potential mechanism
mediating the antidepressant effects ofenhanced A1R expression, we hypothesized a role of homer1a,
since this immediate-early gene product is upregulated by
several antidepressant treatments (Conti et al., 2007; Maret
et al., 2007; Sakagami et al., 2005; Sun et al., 2011) and was
recently implicated in the etiology of major depression (Rietschel
et al., 2010). Thus, we initially checked homer1a mRNA expres-
sion by in situ hybridization (Figures 5A and S3C) and qRT-PCR
(Figures 5C and S3D) in different brain regions of WT and A1 ON
mice. We found significantly increased homer1a mRNA levels in
the cortex, including mPFC and hippocampus, but not in the
striatum of A1 ON mice (Figures 5A, 5C, S3C, and S3D), regions
in which enhanced A1R expression was detected (Figures 1C–
1E). Since in situ hybridization data (Figures 5A and S3C)
matched the results obtained by qRT-PCR (Figures 5C and
S3D), we further used qRT-PCR to evaluate homer1a mRNA
expression. Then Homer1a mRNA expression was analyzed in2, August 5, 2015 ª2015 Elsevier Inc. 553
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Figure 5. Homer1a Expression Level in Medial Prefrontal Cortex Correlates with Mouse Depressive-like Behavior
(A) Densitometric quantifications of homer1amRNA expression levels determined by in situ hybridization in medial prefrontal cortex (mPFC), cortex, striatum, and
hippocampus of WT and A1 ON mice (n = 4). Student’s t test: *p < 0.05, **p < 0.01, n.s., not significant.
(B) qRT-PCR analysis of relative homer1a mRNA expression levels in mPFC, hippocampus, cortex, and striatum of control, chronically despaired (CDM),
despaired mice treated for 4 weeks with Imipramine (Imi), despaired mice sleep deprived for 6 hr (SD), and despaired mice sleep deprived for 6 hr followed
by 18 hr recovery sleep (RS) (n = 6). One-way ANOVA with Bonferroni post hoc test: **p < 0.01 in comparison to control; ##p < 0.01, ###p < 0.001 in comparison
to CDM.
(C) Relative homer1a mRNA expression levels in the mPFC of control and CDM WT, A1 OFF, and A1 ON mice (n = 6).
(D) Representative western blot of homer1a protein expression in mPFC of control and CDM A1 OFF and A1 ON mice.
(legend continued on next page)
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WT animals subjected to the chronic despair paradigm with and
without imipramine treatment or SD. Mice in the state of chronic
despair (CDM) showed reduced homer1a mRNA expression in
the cortex (mPFC and cortex), but not in hippocampus and stria-
tum (Figure 5B). Imipramine treatment only increased homer1a
mRNA expression in the mPFC, whereas SD led to homer1a in-
crease in all examined brain areas (Figure 5B). Thus, homer1a
expression only in the mPFC was inversely correlated to the
depressive-like behavior of WT animals. We therefore further
examined the homer1a levels in transgenic and A1RKO in this re-
gion. We found an increased homer1a mRNA (Figures 5A and
5C) and protein (Figures 5D and 5E) expression in the mPFC of
A1 ON as compared to WT and A1 OFF mice under control con-
ditions or whenmice were subjected to the chronic despair para-
digm. In contrast, A1RKO mice displayed decreased homer1a
mRNA expression in all investigated regions (Figures 5F and
S3D). A1RKO mice, which were resistant to the antidepressant
effects of SD, displayed no significant induction of homer1a
mRNA and protein levels in mPFC after SD (Figures 5F–5H).
This lack of effect on homer1a expression was specific since
another neuronal immediate-early gene Arc was efficiently upre-
gulated in mPFC (Conti et al., 2007) (Figure S3G), indicating that
A1RKO mice are able to respond to SD. Homer1a expression in
mPFCwas strongly upregulated by imipramine treatment in both
WT and A1RKO mice (Figures 5F–5H). In contrast, the expres-
sion of the long splice variant homer1b/c, measured as control,
was not significantly affected, either by the genotype or the treat-
ment (Figures S3E and S3F).
Taken together, these data indicate a significant inverse cor-
relation between mouse depressive-like behavior and homer1a
mRNA expression in the mPFC (Figure 5I). The mice can be
divided into three significantly different groups, according to
these factors: ‘‘DESPAIRED’’ with high immobility time and low
homer1a expression; ‘‘CONTROL’’ with moderate immobility
time and homer1a expression; and ‘‘ANTIDEPRESSANT’’ with
low immobility time and high homer1a expression (Figure 5I).
A1R Signaling Induces Homer1a Expression in Primary
Neuronal Cultures and Mouse Cortex
As homer1a mRNA expression was increased in all investigated
brain regions of A1 ON mice, where enhanced A1R expression
was detected (Figures 5A, S3C, and S3D), we asked whether
A1R stimulation leads to homer1a induction. Indeed, we found(E) Densitometric quantification of homer1a protein expression levels in mPFC o
(F) Relative homer1a mRNA expression levels in the mPFC of control, CDM, Imi,
(G) Representative western blot of homer1a protein expression in mPFC of cont
(H) Densitometric quantification of homer1a protein expression levels in mPFC o
Two-way ANOVA with Bonferroni post hoc test: *p < 0.05, **p < 0.01; #p < 0.05,
xxxp < 0.001 in comparison to CDM.
(I) Homer1a mRNA level in mPFC correlates with mouse depressive-like behav
homer1a mRNA relative expression in mPFC and the immobility time spent in da
0.7383; p < 0.001). Themice formed three significantly different groups: DESPAIR
A1RKO [control] and chronically despaired [CDM] WT, A1 OFF, A1RKO, and sle
levels of immobility time and homer1a expression (control WT and A1 OFF, and
mice); ANTIDEPRESSANT (red circled) with low immobility time and high homer1
imipramine or SD). Two-way ANOVA with Bonferroni post hoc test: *p < 0.05, **p
Data are expressed as the means ± SEM.
See also Figures S3C–S3G and S4 and Table S1.that the adenosine receptors agonist NECA rapidly but tran-
siently upregulated homer1a mRNA (Figure 6A) and protein (Fig-
ures 6C, 6D, and S3I) in cultured primary neurons. This homer1a
induction was absent in primary neurons from A1RKO mice
(Figures 6B–6D), indicating the involvement of A1R. As a posi-
tive control, NMDA stimulation similarly induced homer1a
mRNA expression in the cultures from both strains (Figures 6A
and 6B). No effect of NECA was found on homer1b/c levels,
measured as control (Figure S3H). We investigated further the
A1R-dependent increase of homer1a expression by applying
several different inhibitors of A1R signaling. Thus, we pretreated
neuronal cultures for 30 min with G protein blocker pertussis
toxin (10 ng/ml; PTX), PLC inhibitor U37122 (50 mM), or ERK1,2
inhibitor PD98058 (30 mM) prior to the NECA stimulation. These
inhibitors completely abolished the NECA-mediated increase
of homer1a mRNA expression (Figure 6E), indicating that the
ERK-pathway is involved in the homer1a upregulation. Indeed,
in vivo i.p. application of of A1R agonist MRS5474 (3 mg/kg)
strongly increased ERK1,2 phosphorylation (Figure 6F) and
significantly induced homer1a protein expression (Figure 6G) in
the mouse cortex after 1 hr.
SiRNA Knockdown of Homer1a Expression in mPFC
Inhibits the Antidepressant Effects of Enhanced A1R
Expression, SD, Imipramine, and Ketamine Treatment
To investigate whether the action of antidepressant treatments is
due to the increased homer1a expression, we knocked down
the homer1a mRNA specifically in the mPFC using custom-
designed anti-homer1a Accell siRNA (see the Supplemental
Experimental Procedures in the Supplemental Information and
Figure S8 formore details about siRNA design and in vitro testing
of the efficacy). SiRNA downregulation of Homer1a in the mPFC
(Figure 7E) significantly increased the depressive-like behavior of
WT mice and inhibited the antidepressant effect of enhanced
A1R expression in A1 ON mice (Figure 7B). However, sihomer1a
had no significant effect on the spontaneous locomotor activity
(Figure 7A) and anxiety-like behavior (Figure S7C) of the mice
in open field test.
To check whether homer1a is necessary for the antidepres-
sant effect of SD, we injected sihomer1a in the mPFC of
chronically despaired WT mice 2 days prior to the SD and
the test phase (Figure 7C). Since chronically despaired mice
had already low homer1a expression in the mPFC, comparedf control and CDM A1 OFF and A1 ON mice normalized to actin (n = 4).
SD, and RS WT and A1RKO mice (n = 6).
rol, CDM, Imi, and SD WT and A1RKO mice.
f control, CDM, Imi, and SD WT and A1RKO mice normalized to actin (n = 4).
##p < 0.01, ###p < 0.001 in comparison to control and xp < 0.05, xxp < 0.01,
ior. The linear regression line represents the significant correlation between
y 2 of FST or test phase (Pearson product-moment correlation coefficient R2 =
ED (blue circled) with high immobility time and low homer1a expression (control
ep-deprived A1RKO [CDM+SD] mice); CONTROL (green circled) with middle
chronically despaired A1 ON and A1RKO treated with imipramine (CDM+Imi)
a expression (control A1 ON and chronically despaired WT mice treated with
< 0.01.
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Figure 6. A1R Signaling Induces Homer1a Expression in Primary Neuronal Cultures and Mouse Cortex
(A) Relative homer1a mRNA expression levels in WT primary neurons stimulated with 1 mM NECA or 10 mM NMDA for indicated time periods (n = 4).
(B) Relative homer1a mRNA expression levels in A1RKO primary neurons stimulated with 1 mM NECA or 10 mM NMDA for indicated time periods (n = 3).
(C) Representative western blots of homer1a protein expression in 1 mM NECA stimulated primary neurons from WT and A1RKO mice.
(D) Densitometric quantification of homer1a protein expression in 1 mM NECA stimulated primary neurons from WT and A1RKO mice (n = 3).
(E) Relative homer1a mRNA expression levels in WT primary neurons pretreated 30 min, prior to 1 mMNECA stimulation, with different inhibitors of A1R signaling
cascade (10 ng/ml PTX, 50 mM U37122, and 30 mM PD98058) for indicated time periods (n = 3).
One-way ANOVA with Bonferroni post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 in comparison to Cntr.
(F and G) Representative western blots and densitometric quantifications of ERK1,2 phosphorylation (F) and homer1a protein expression level (G) in the cortex of
mice 1 hr after i.p. injection of saline (Sal) or 3 mg/kg A1R agonist MRS5474 (MRS) (n = 3). Student’s t test: *p < 0.05, **p < 0.01.
Data are expressed as the means ± SEM.
See also Figures S3H, S3I, and S4 and Table S1.to naive controls (Figures 5), the further downregulation of
homer1a by siRNA (Figure 7E) did not affect the immobility
time of the animals during the test phase (Figure 7D). However,
sihomer1a injections completely inhibited both the homer1a in-556 Neuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc.duction (Figure 7E) and the antidepressant effect of 6 hr SD
(Figure 7D).
We further tested whether homer1a downregulation in the
mPFC inhibits the antidepressant effects of imipramine and
A B
C
D E
Figure 7. Knockdown of Homer1a Expression with siRNA in mPFC Inhibits the Antidepressant Effects of Enhanced A1R Expression, Sleep
Deprivation, Imipramine, and Ketamine Treatment
(A) Spontaneous activity in open field test of WT mice stereotaxically bilaterally injected with anti-homer1a (sihomer1a) (n = 7) or non-target control (siCntr) (n = 7)
siRNA into mPFC.
(B) Immobility time during day 2 of FST of WT (n = 14) and A1 ON (n = 12) mice plotted in seconds (left) and as percentage of WT (right). The animals were
stereotaxically bilaterally injected with anti-homer1a (sihomer1a) or non-target control (siCntr) siRNA into mPFC and 2 days later subjected to FST. Two-way
ANOVA with Bonferroni post hoc test: *p < 0.05, **p < 0.01; #p < 0.05, ##p < 0.01 in comparison to siCntr.
(C) Schematic illustration of the experimental protocol. WTmice were despaired by 10 min swim sessions for 5 consecutive days (day 1 to day 5). The mice were
kept undisturbed in their home cages for 4 weeks and divided into four groups: CDM, chronically despairedmice; SD, CDMsubjected to 6 hr SD; Imi, CDM treated
with imipramine I the drinking water for 4 weeks; Ket, CDM treated with ketamine 1 hr before the test phase. On day 30 the mice were siRNA injected into mPFC
and the last 10 min swim session (test phase) was performed on day 32.
(D) Immobility time during the test phase of CDM, SD, Imi, and Ket mice injected with siCntr or sihomer1a into mPFC (n = 12). Two-way ANOVA with Bonferroni
post hoc test: **p < 0.01; ##p < 0.01 in comparison to CDM.
(E) Relative homer1a mRNA expression levels in mPFC of WT, A1 ON, CDM, SD, Imi, and Ket mice injected with siCntr or sihomer1a into mPFC (n = 12). Two-way
ANOVA with Bonferroni post hoc test: **p < 0.01; #p < 0.05, ##p < 0.01 in comparison to WT, xxxp < 0.001 in comparison to CDM.
Data are expressed as the means ± SEM.
See also Figures S5, S6, and S7.ketamine. While at least 2 weeks of imipramine (20 mg/kg/day)
treatment is necessary to promote antidepressant effects in
CDM mice (Figure S5A) and induce homer1a mRNA levels in
the mPFC of chronically despaired mice (Figure S5C), only a sin-
gle i.p. injection of ketamine (3 mg/kg) was sufficient to promote
rapid and long-lasting antidepressant effects (Figure S5B) and
sustained significant increase of homer1a mRNA expression in
the mPFC (Figure S5C). Sihomer1a injections into mPFC signifi-
cantly suppressed both the homer1a induction (Figure 7E) and
the antidepressant effects of chronic imipramine and acute keta-mine treatment (Figure 7D). Taken together, these data point
toward a general importance of homer1a for anti-depressive
therapy.
Viral Overexpression of Homer1a in mPFC Promotes
Antidepressant Effects in Chronically Despaired Mice
To address directly the role of increased homer1a expression on
the mouse depressive-like behavior, we used recombinant ad-
eno-associated viral vectors (rAAVs) carrying Homer1a (h1aV),
mutated Homer1aW24A (h1aV(W24A)), which is unable to bindNeuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc. 557
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Figure 8. Intra-mPFC Injection of rAAV-Homer1a
Promotes Antidepressant Effects in Chronically
Despaired Mice
(A) Schematic illustration of the experimental protocol:
WT mice were despaired by 10 min swim sessions for 5
consecutive days (day 1 to day 5) followed by stereo-
taxical bilateral injection of rAAV into mPFC. The mice
were kept undisturbed in their home cages for 4 weeks
and then subjected to open field test (OF) (day 30), TST
(day 31), FST (day 32), and SPT (day 32 to day 35).
(B) Spontaneous activity in OF: total distance of move-
ment of CDM WT mice injected with of rAAV-EGFP
(EGFP) (n = 5), rAAV-Homer1aVenus(W24A)
(h1aV(W24A)) (n = 4), or rAAV-Homer1aVenus (h1aV) (n =
10) into mPFC.
(C) Immobility time in TST.
(D) Immobility time in FST.
(E) Sucrose preference in SPT.
One-way ANOVA with Bonferroni post hoc test: *p <
0.05, **p < 0.01, ***p < 0.001.
Data are expressed as the means ± SEM.
See also Figure S7.proline-rich motifs, and EGFP cDNA, used as control (Lominac
et al., 2005). Chronically despairedWTmice were stereotaxically
bilaterally injected with rAAV into mPFC on day 6 immediately
after the training phase (Figure 8A) and behaviorally tested
4 weeks later. rAAV-mediated overexpression of homer1a did
not affect the spontaneous locomotor activity (Figure 8B) and
the anxiety-like behavior (Figure S7D) of the mice in open field
test. However, homer1a-injected mice showed strongly reduced
depression-like behavior in TST (Figure 8C) and FST (Figure 8D)
and significantly increased sucrose consumption in SPT (Fig-
ure 8E), in comparison to the control mice expressing mutated
h1aV(W24A) or EGFP.
DISCUSSION
Numerous studies have suggested a potential role of adenosi-
nergic signaling in the mechanism of action of SD, ECT, and
DBS (Bekar et al., 2008; Hamani et al., 2010; Hines et al.,
2013; Sadek et al., 2011; van Calker and Biber, 2005). To analyze
directly the potential antidepressant effects of increased A1R558 Neuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc.signaling, we have created a transgenicmouse
model with conditioned upregulation of A1R
selectively in forebrain neurons. In order to
maximize the specificity, we used the fore-
brain neuron-specific CaMKII promoter and
Tet-OFF system, avoiding potential artifacts
of the transgene during development. The
transgene expression in our mouse model
generated levels of A1R upregulation compa-
rable to what is known in animal and human
brain in response to seizures or sleep depriva-
tion (Biber et al., 2008; Elmenhorst et al., 2007,
2009; Vanore et al., 2001).
Our behavioral analyses demonstrated that
upregulation of A1R caused a robust anxiolytic
effect but did not affect spontaneous activity,exploratory behavior, spatial learning, or recognition and work-
ing memory. These results are in line with findings published
using A1RKO mice, which demonstrate increased anxiety-like
behavior without affecting motor performance, exploration, or
learning and memory (Gime´nez-Llort et al., 2002; Johansson
et al., 2001; Lang et al., 2003). Moreover, our data corroborate
the importance of A1R in controlling anxiety behavior in both ro-
dents (Prediger et al., 2006) and humans, as it was published
recently that individuals with increased anxiety also show
changes in A1R binding in vivo (Hohoff et al., 2014).
The two basic tests for depressive-like behavior TST and the
classical FST revealed significant antidepressant effects of the
enhanced A1R expression. We further validated the antidepres-
sant effects of upregulated A1R in an experimental model of
chronic depression that causes a chronic state of behavioral
despair for at least 4 weeks (Kumar et al., 2010; Stone and Lin,
2011; Sun et al., 2011). The chronic maintenance of the depres-
sion-like state in this model was confirmed by TST and by
SPT. The time frame of 4 weeks, between the induction and
test phase, offered the possibility of therapeutic intervention.
Inducing A1R expression in our model reduced the immobility
time and increased the sucrose preference similarly to the anti-
depressant effects of 4 weeks treatment with imipramine or
6 hr of SD. Thus, the enhanced A1R expression not only provides
protective antidepressant effect against the development of
depressive-like behavior, but also elicits ‘‘therapeutic’’ effects
in mice with already induced chronic depression-like behavioral
symptoms.
On the other hand, A1R deficiency sensitizes to depressive-
like behavior and obviates the antidepressant-like response to
SD. Thus, it is concluded that A1R are crucial for the antidepres-
sant effects of SD. These results confirm and extend recent find-
ings showing that the SD-induced antidepressant effects are
due to adenosine release from astrocytes, which acts via aden-
osine A1R presumably expressed on neurons (Hines et al., 2013).
However, the observed increased depression-like behavior of
A1RKO mice in our experiments differed from previously pub-
lished studies using another A1RKO mouse strain (Hines et al.,
2013; Sun et al., 2001). Indeed, other behavioral differences be-
tween the two A1RKO mouse lines were reported previously,
which might be the result of distinct genetic background or
different testing conditions (Gime´nez-Llort et al., 2002; Johans-
son et al., 2001; Lang et al., 2003).
Furthermore, we describe here an antidepressant effect of the
selective A1R agonist MRS5474 (Tosh et al., 2012). MRS5474
has been recently developed as a potent selective A1R agonist
that is active in the CNS upon peripheral administration without
cardiovascular side effects. This allows i.p application and toler-
ability over a wide dose range, unlike all other known A1R
agonists, and it has less effect on the locomotor activity of the
animals (Tosh et al., 2012). These data not only corroborate
the crucial role of A1R in depressive-like behavior but point to-
ward potential new therapeutic possibilities of peripheral appli-
cation of A1R agonists. MRS5474 had a rapid and relatively
short-term antidepressant effect in both classical FST and
chronically despaired mice. Likewise, the antidepressant effects
promoted by SD and i.c.v. treatment with A1R agonists are only
transient (Hines et al., 2013), suggesting that A1R is rapidly de-
sensitized. Our data also show that if desensitization is counter-
balanced by transgenic expression, as in our mouse model, the
antidepressant effects of A1R persist. Thus, the enhanced A1R
function is directly coupled to the antidepressant effect.
As one possible mechanism mediating the antidepressant
effects of enhanced A1R expression, we considered a role of
homer1a. A potential involvement of homer1a in depression-
like behavior has been suggested in earlier reports (Kato, 2009;
Lominac et al., 2005; Rietschel et al., 2010; Sakagami et al.,
2005; Sun et al., 2011; Szumlinski et al., 2006). Interestingly,
homer1a is upregulated by SD and ECT, antidepressant thera-
pies also associated with increased A1R signaling (Conti et al.,
2007; Elmenhorst et al., 2007, 2009; Maret et al., 2007; Sadek
et al., 2011; Sakagami et al., 2005). The investigation of the hom-
er1a levels in A1 ON and A1RKO mice in combination with our
in vitro studies clearly demonstrates that A1R regulates homer1a
expression. A1R are usually coupled with Gi proteins, which
inhibit cAMP formation (Fredholm et al., 2001), but when highly
expressed in cells (for example, neurons or smooth muscle
cells), A1R can also regulate phospholipase C (Biber et al.,1997; Fenton et al., 2010; Robin et al., 2011; Rogel et al., 2006)
and MAPK pathway (Kunduri et al., 2013; Migita et al., 2008).
Indeed, blocking this pathway completely abolished the NECA-
mediated increase of homer1a expression in primary neurons.
In addition, MRS5474 induces ERK1,2 activation and homer1a
levels in the mouse cortex, corroborating previous reports on
ERKs in homer1a regulation (Mahan et al., 2012; Sato et al.,
2001) and providing evidence for the importance of this signaling
route in the normal brain.
The molecular mechanism of SD is poorly understood, but the
potential role of several immediate-early genes, including Arc
and homer1a, has been suggested (Benedetti and Colombo,
2011; Conti et al., 2007; Grønli et al., 2013; Maret et al., 2007).
We have shown here that the A1RKO mice are resistant to the
antidepressant effect of SD and show no significant induction
of homer1a levels in the mPFC after SD. In contrast, Arc expres-
sion was increased in A1RKO (Figure S3G), serving as positive
control. Thus, the antidepressant effects of SD appear to be
due to the A1R-mediated induction of homer1a.
We have found that the antidepressant effects mediated by
the enhanced A1R expression, SD, imipramine, and ketamine
treatment are all accompanied by and strictly dependent on an
increased expression of homer1a specifically in the mPFC. We
show here that in vivo anti-homer1a Accell siRNA injections
(Nakajima et al., 2012) decreased homer1a mRNA in the mPFC
to levels similar to that found in chronically despaired mice.
Indeed, this downregulation increased the depressive-like
behavior of WT animals and obviated the antidepressant effects
of enhanced A1R signaling (A1 ON mice and in WT animals after
SD). The siRNA effect was more obvious in the SD experiment
as here CDMmice were used that express low levels of homer1a.
Homer1a was also found upregulated by treatment with classical
antidepressants, such as imipramine and fluoxetine, as well
as ketamine, a compound producing very rapid and sustained
antidepressant effects also in humans (Browne and Lucki,
2013), extending preliminary results by others (Conti et al., 2007;
Serres et al., 2012; Sun et al., 2011). Sihomer1a application into
mPFC inhibitedhomer1a induction andprevented theantidepres-
sant effects caused by chronic imipramine and acute ketamine
treatment. Indeed, depressive-like behavior correlated signifi-
cantly with homer1a mRNA expression in the mPFC (Figure 5I).
How ketamine or imipramine treatment leads to enhanced
homer1a expression in the mPFC is unclear but direct effects
of both drugs in the mPFC seem unlikely. Ketamine as NMDA re-
ceptor antagonist may not have a direct effect on homer1a as
NMDA receptors usually are inducers of homer1a in neurons.
Accordingly, studies that show direct effects of ketamine on
Homer1a in neurons are currently not available. The fact that in
CDM mice imipramine needs to be given for at least 2 weeks
to increase Homer1a argues against a direct effect of imipramine
in the mPFC. We hypothesize that ketamine and imipramine
change the network activity of the brain and that as a common
result of those changes Homer1a in the mPFC is upregulated.
Indeed, changes in brain network activity are discussed as
instrumental for depression and its treatment (Voytek and
Knight, 2015).
Importantly, viral overexpression of homer1a in themPFC pro-
motes antidepressant effects in chronically despaired mice inNeuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc. 559
several behavioral tests. These observations extend further
the earlier findings describing that overexpression of homer1a
ameliorated the increased depression-like behavior of homer1
KO mice (Lominac et al., 2005). While some reports suggested
that homer1a is implicated in several neuropsychiatric disorders
(Szumlinski et al., 2006), we demonstrated here that changes of
homer1a levels in the mPFC has no significant effect on the anx-
iety-like behavior, spontaneous activity, and exploratory drive
(Figure S7).
How homer1a mediates antidepressant effects is currently
not understood. The long homer scaffolds are bridging metabo-
tropic glutamate receptors with many proteins involved in Ca2+
signaling (Fagni et al., 2000; Jardin et al., 2013), which have
been implicated in the pathophysiology of mood disorders
(Galeotti et al., 2008a, 2008b). The short homer1a is lacking
the carboxyl-terminal domain and is considered as a domi-
nant-negative regulator of these interactions by disrupting
homer clusters by competitive binding to target proteins (Kam-
mermeier and Worley, 2007; Shiraishi-Yamaguchi and Furuichi,
2007). Its general role is thought to involve an activity-dependent
synaptic reorganization (Hu et al., 2010; Inoue et al., 2007) that
provides flexible adaptation to environmental demands. Thus,
as much as clinical depression can be seen as the result of failed
adaptation to stress, homer1a upregulation might evoke its anti-
depressant effects by improving synaptic reorganization in neu-
ral networks salient for mood regulation. Indeed, homer1a has
been identified as a member of the hitherto enigmatic group of
plasticity-related proteins that promote synaptic reorganization
by stabilizing ‘‘tagged’’ synapses (Okada et al., 2009; Worley
and Shuler, 2014), as predicted by the ‘‘tagging and capture’’ hy-
pothesis of memory formation (Redondo and Morris, 2011).
Taken together, enhanced A1R expression (in transgenic mice
or induced by SD) provides protection against acquisition of
depressive-like behavior and therapeutic effects when depres-
sion-like behavior is already induced, bothmediated by homer1a
upregulation in the mPFC. It is suggested that similar mecha-
nisms are also present in antidepressant therapies used in
patients, like ECT, DBS, or transcranial magnetic stimulation,
where enhanced A1R signaling has been reported (Bekar et al.,
2008; Hamani et al., 2010; Kato, 2009; Sakagami et al., 2005).
Since homer1a is upregulated by several different antidepres-
sant treatments, including those with a very rapid effect like ke-
tamine, it is concluded that homer1a induction is a crucial joint
mechanism mediating the antidepressant effects. As in humans,
homer1 gene variants have been associated with the etiology of
major depression (Rietschel et al., 2010) our findings provide
potential insights into the general mechanism of antidepressant
therapy.
EXPERIMENTAL PROCEDURES
See the Supplemental Experimental Procedures in the Supplemental Informa-
tion for more details.
Mice
All procedures were performed in accordance with the German animal protec-
tion law, FELASA, the national animal welfare body GV-SOLAS, and NIH guide
for thecare anduseof laboratory animals andwere approvedby theanimalwel-
fare committee of the University of Freiburg, University of Bonn, University of560 Neuron 87, 549–562, August 5, 2015 ª2015 Elsevier Inc.Naples, and NIH. The adenosine A1 receptor knockout mouse line (A1RKO)
used in this study was previously described (Sun et al., 2001).
Behavioral Studies
Activity and behavior of mice were observed using an automatic video-tracking
system for recording and analysis (VideoMot2 systemV6.01, TSE), unless other-
wise specified. One cohort of mice was used to perform the open field, object
recognition test, light/dark transition test, T-maze, elevatedplusmaze, andMor-
ris watermaze and another cohort was used for the classical tail suspension and
forced swim tests. The chronic behavioral despair induced by repeated swim
stress and sucrose preference test was performed with both cohorts.
Chronic Behavioral Despair Model
In order to induce chronic behavioral despair in mice, we used a recently
described protocol (Sun et al., 2011). Themice were subjected to repeat swim-
ming in a transparent cylinder (15 cm diameter) containing 20 cm of water
(22–25C) for 10 min daily for 5 consecutive days (induction phase). From
day 6 on, the mice were kept in the home cage without swimming for 4 weeks,
after which a last swim was imposed on day 32 (test phase). The immobility
time and the swum distance of the mice were analyzed in each session. The
repeated exposure to swimming significantly increased the immobility time
and decreased the traveled distance over this 5 day period. This induced state
of behavioral despair was chronically maintained for 4 weeks (till day 32) and
represent a model for depressive-like behavior in mice (Sun et al., 2011).
Other Behavioral Studies, Immunohistochemistry, In Situ
Hybridization, Quantitative Real-Time PCR, Western Blot Analysis,
Primary Neuronal Cultures, and In Vitro siRNA Interference
See the Supplemental Experimental Procedures.
In Vivo Stereotaxic Microinjections of siRNA and Recombinant
Adeno-Associated Viral Vectors
Endotoxin-free FAM-labeled Accell Green non-targeting control siRNA and the
in vitro tested si2: 50-CAGCAATCATGATTAAGTA-30 (Moutin et al., 2012)
anti-homer1a Accell siRNA (Thermo Fisher Scientific) (Nakajima et al., 2012)
(2 mg/ml) dissolved in Accell siRNA delivery media (Thermo Fisher Scien-
tific) were stereotaxically bilaterally injected with a Hamilton syringe fitted
with a 33G needle aimed above the mPFC (anteroposterior +1.34 mm,
mediolateral ± 0.6 mm, dorsoventral 2.0 mm, relative to bregma) (Lominac
et al., 2005) at a rate of 0.1 ml/min for 5 min (total volume of 0.5 ml/side). The
injection needle was shortly left in place and slowly withdrawn (1mm/min) after
the injection. Afterward, animals were allowed to recover and treated for 24 hr
with Metamizole (200 mg/kg daily dose) (Zentiva) in drinking water. Behavioral
testing commenced 2 days after the injection. The siRNA transfection efficacy
and localization was verified by qRT-PCR and immunohistochemistry.
For stereotaxic injections of rAAVs (Celikel et al., 2007), 1.5 ml of either, rAAV-
EGFP, -h1aV, or -h1aV(W24A) (2 3 1,011 particles/ml) were injected bilater-
ally into the mPFC (Lominac et al., 2005) at a rate of 100 nl/min with a 10-ml
syringe fitted with a 34G bevelled needle by amicroprocessor-controlled mini-
pump (World Precision Instruments). Behavioral testing began 4 weeks after
the rAAV injections.
Statistical Analyses
The statistical analyses were performed using ANOVA with Bonferroni post
hoc comparison or unpaired Student’s t tests. The significance level for all of
the tests was set at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2015.07.010.
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